Active is: Inventing new opportunities

China reaches for the STAR market

19/01/2021
Old building in China

Summary

China’s nascent STAR market provides a platform for the technology and science firms that increasingly underpin the country’s growth story.

Key takeaways

  • China’s new STAR market has been billed as the country’s answer to the Nasdaq – the technology-focused US exchange
  • Its listing rules make it easier for the country’s tech and science startups to list domestically, thereby supporting the fast-growing sectors that are driving China’s growth
  • Since opening in July 2019 with 25 listings, the STAR market now comprises almost 200 firms – and nearly 500 are in the IPO pipeline.

Once famed as the world’s low-cost manufacturer, China has spent much of the last decade positioning itself to better compete with high-quality foreign peers across the value chain. The government has sought to establish China at the cutting edge of technological advances, especially in the areas of biotech, information technology, healthcare, and robotics – and as a manufacturer of the components necessary to support those fields. In doing so, it has begun a new chapter in its growth story.

To drive further growth in these areas and encourage companies to list onshore, China launched a new exchange on its Shanghai stock market in June 2019. Billed as China’s answer to Nasdaq, the STAR market is specifically designed to house companies in high-tech and strategic emerging sectors, and to facilitate funding to these firms.

What the STAR market offers

Before the STAR market’s launch, all Chinese A-shares were listed on one of the three boards that made up the Shanghai and Shenzhen-based stock exchanges.

The new STAR market aims to streamline the IPO process for innovative growth companies, using a flexible and transparent registration model. The market has no minimum profitability requirement for listing companies, supporting those organisations which may take time to realise a commercial profit, such as those in the biopharmaceutical space.

As detailed in Table 1, the STAR market also introduces a new approach to pricing mechanism, investor eligibility and delisting rules, selectively lifting best practices from stock exchanges in the US, Hong Kong and Singapore.

The existing A-shares markets that have provided the platform for China’s growth story so far could also follow the STAR market’s lead, and any further liberalisation of China’s capital markets – driving greater institutional participation – would likely encourage more Chinese firms to list domestically instead of on US exchanges. Such a trend should reduce the risk premium for all China A-shares over time.

TABLE 1: How STAR market addresses the existing Chinese boards’ inefficiencies

 
STAR market
Current China A-Shares (Shanghai & Shenzhen Mainboard, SME and Chinext)
Listing criteria
  • Companies without profitability track record are allowed
  • Dual share class with different voting rights allowed
  • VIE structure allowed
  • Registration-based, transparent process
  • Minimum total profitability, revenue and assets requirement
  • Dual share class and VIE structures not allowed
  • Approval-based IPO process
Pricing mechanism
  • Market-based pricing, no implicit cap
  • Implicit pricing cap around 23 x price to earnings
Trading mechanism
  • +/- 20% daily price limit
  • +/- 10% daily price limit
Investor eligibility
  • Encourage participation of institutional investors; higher entry barrier for retail investors
  • Only QFII and RQFII allowed
  • All investors can participate
  • Hot IPOs very often have 90% allocated to retail individuals
  • Full access for RQFII and QFII investors; partial access for Stock Connect investors
Delisting rules
  • Better defined de-listing rules, stricter implementation
Poor implementation of delisting rules

The STAR market has quickly become established

Investors and companies alike have so far been quick to embrace the STAR market. After launching in July 2019 with 25 names, the market had grown to 215 listed companies by January 2021. There are currently around 500 firms at different stages of the IPO registration pipeline.

What’s more, stocks listed on the STAR market are steadily becoming more accessible to non-Chinese investors, offering a new route into the tech startups behind the country’s growth story. The FTSE already has plans in place to include the STAR market in its share indices, although MSCI – the world’s primary index provider – has not yet detailed how it will treat the new market.

While the STAR market has had a relatively big impact in a short space of time, it has further to go to become an established fixture for investors. There were liquidity concerns in the market’s early days, particularly around larger IPOs soaking up available capital, but by and large the market has functioned smoothly. Even so, stocks listed on the STAR market are not yet eligible for the Stock Connect scheme – which makes A-shares more easily available to western investors – so many global institutional investors will not be able to participate.

Chinese regulators are set to keep a close eye on the STAR market, given its combination of a lighter regulatory framework and likely increased volatility due to the high-risk early-stage companies that populate the market. Putting a value on these companies will also test the valuation methodologies of brokers and investors alike.

But despite these challenges, the STAR market has enjoyed a rapid expansion so far, and the pipeline of potential new admissions bodes well for the future of this market – and the resulting opportunities for global investors to access some of the most innovative Chinese firms.

1473397

Preparing for the reference rate change

22/06/2021
Preparing for the reference rate change

Summary

After the Financial Crisis, InterBank Offered Rates (IBORs) have been declared unreliable by Regulators and new Alternative Reference Rates transactions-based have been developed to substitute these indices. Consequently, most of the IBORs will cease to be published from December 2021. As IBORs are used in a broad range of financial products and contracts, market participants need to be prepared and work on a plan to move away from them.

Key takeaways

  • Most of InterBank Offered Rates (IBORs) are going be discontinued from December 2021
  • New Alternative Reference Rates (ARR) have been identified and developed to substitute IBORs
  • Regulators are publishing guidelines to encourage and support the private market participant in the change.
  • Investing involves risk. The value of an investment and the income from it will fluctuate and investors may not get back the principal invested. Past performance is not indicative of future performance. This is a marketing communication. It is for informational purposes only. This document does not constitute investment advice or a recommendation to buy, sell or hold any security and shall not be deemed an offer to sell or a solicitation of an offer to buy any security. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. Certain data used are derived from various sources believed to be reliable, but the accuracy or completeness of the data is not guaranteed and no liability is assumed for any direct or consequential losses arising from their use. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted.

    This material has not been reviewed by any regulatory authorities. In mainland China, it is for Qualified Domestic Institutional Investors scheme pursuant to applicable rules and regulations and is for information purpose only. This document does not constitute a public offer by virtue of Act Number 26.831 of the Argentine Republic and General Resolution No. 622/2013 of the NSC. This communication's sole purpose is to inform and does not under any circumstance constitute promotion or publicity of Allianz Global Investors products and/or services in Colombia or to Colombian residents pursuant to part 4 of Decree 2555 of 2010. This communication does not in any way aim to directly or indirectly initiate the purchase of a product or the provision of a service offered by Allianz Global Investors. Via reception of his document, each resident in Colombia acknowledges and accepts to have contacted Allianz Global Investors via their own initiative and that the communication under no circumstances does not arise from any promotional or marketing activities carried out by Allianz Global Investors. Colombian residents accept that accessing any type of social network page of Allianz Global Investors is done under their own responsibility and initiative and are aware that they may access specific information on the products and services of Allianz Global Investors. This communication is strictly private and confidential and may not be reproduced. This communication does not constitute a public offer of securities in Colombia pursuant to the public offer regulation set forth in Decree 2555 of 2010. This communication and the information provided herein should not be considered a solicitation or an offer by Allianz Global Investors or its affiliates to provide any financial products in Brazil, Panama, Peru, and Uruguay. In Australia, this material is presented by Allianz Global Investors Asia Pacific Limited (“AllianzGI AP”) and is intended for the use of investment consultants and other institutional/professional investors only, and is not directed to the public or individual retail investors. AllianzGI AP is not licensed to provide financial services to retail clients in Australia. AllianzGI AP is exempt from the requirement to hold an Australian Foreign Financial Service License under the Corporations Act 2001 (Cth) pursuant to ASIC Class Order (CO 03/1103) with respect to the provision of financial services to wholesale clients only. AllianzGI AP is licensed and regulated by Hong Kong Securities and Futures Commission under Hong Kong laws, which differ from Australian laws.

    This document is being distributed by the following Allianz Global Investors companies: Allianz Global Investors GmbH, an investment company in Germany, authorized by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin); Allianz Global Investors (Schweiz) AG; in HK, by Allianz Global Investors Asia Pacific Ltd., licensed by the Hong Kong Securities and Futures Commission; in Singapore, by Allianz Global Investors Singapore Ltd., regulated by the Monetary Authority of Singapore [Company Registration No. 199907169Z]; in Japan, by Allianz Global Investors Japan Co., Ltd., registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 424], Member of Japan Investment Advisers Association, the Investment Trust Association, Japan and Type II Financial Instruments Firms Association; in Taiwan, by Allianz Global Investors Taiwan Ltd., licensed by Financial Supervisory Commission in Taiwan; and in Indonesia, by PT. Allianz Global Investors Asset Management Indonesia licensed by Indonesia Financial Services Authority (OJK).

Allianz Global Investors

You are leaving this website and being re-directed to the below website. This does not imply any approval or endorsement of the information by Allianz Global Investors Asia Pacific Limited contained in the redirected website nor does Allianz Global Investors Asia Pacific Limited accept any responsibility or liability in connection with this hyperlink and the information contained herein. Please keep in mind that the redirected website may contain funds and strategies not authorized for offering to the public in your jurisdiction. Besides, please also take note on the redirected website’s terms and conditions, privacy and security policies, or other legal information. By clicking “Continue”, you confirm you acknowledge the details mentioned above and would like to continue accessing the redirected website. Please click “Stay here” if you have any concerns.